Clinicians Treating Refractory Relapse ALL Should Consider Using Inotuzumab - 102191

Spotlight
Video

Clinicians Treating Refractory Relapse ALL Should Consider Using Inotuzumab

Cancer-News has 28 videos Subscribe Here

Loading........
Description: Hagop M. Kantarjian, MD of MD Anderson Cancer Center's Department of Leukemia says now that Besponsa or Inotuzumab is FDA approved that clinicians clinicians treating refractory relapse ALL should consider Inotuzumab for their patients.
Shared By : Cancer-News
Posted on : 08/31/17
Added : 5 months ago



Recommended

Nothing found.

More From Cancer-News

Nothing found.